Revance Therapeutics Company Profile (NASDAQ:RVNC)

About Revance Therapeutics

Revance Therapeutics logoRevance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RVNC
  • CUSIP:
Key Metrics:
  • Previous Close: $15.51
  • 50 Day Moving Average: $13.92
  • 200 Day Moving Average: $16.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.07
  • P/E Growth: -0.37
  • Market Cap: $441.79M
  • Outstanding Shares: 28,484,000
  • Beta: 1.36
Additional Links:
Companies Related to Revance Therapeutics:

Analyst Ratings

Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $43.80 (182.40% upside)

Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
DateFirmActionRatingPrice TargetDetails
8/5/2016Brean CapitalReiterated RatingHoldView Rating Details
6/14/2016SunTrust Banks Inc.Lower Price TargetBuy$46.00 -> $22.00View Rating Details
6/14/2016Piper Jaffray Cos.Reiterated RatingOverweight$54.00 -> $35.00View Rating Details
6/14/2016GuggenheimReiterated RatingBuy$55.00View Rating Details
12/30/2015Cowen and CompanyReiterated RatingBuyView Rating Details
11/10/2015William BlairReiterated RatingBuy$59.00View Rating Details
6/6/2015BMO Capital MarketsReiterated RatingOutperform$24.00 -> $35.00View Rating Details
(Data available from 8/23/2014 forward)


Earnings History for Revance Therapeutics (NASDAQ:RVNC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.86)($0.88)$0.06 million$0.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.83)($0.71)$0.08 millionViewListenView Earnings Details
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q415($0.84)($0.71)ViewN/AView Earnings Details
5/13/2015Q1($0.69)($0.65)ViewListenView Earnings Details
3/2/2015($0.53)($0.60)ViewN/AView Earnings Details
11/12/2014Q314($0.69)($0.60)ViewN/AView Earnings Details
8/12/2014($0.68)($0.69)ViewN/AView Earnings Details
5/13/2014Q1 14($0.87)($1.93)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
Current Year EPS Consensus Estimate: $-3.53 EPS
Next Year EPS Consensus Estimate: $-3.06 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.07)($0.66)($0.87)
Q2 20162($0.91)($0.91)($0.91)
Q3 20162($0.95)($0.93)($0.94)
Q4 20162($1.02)($0.95)($0.99)
(Data provided by Zacks Investment Research)


Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Revance Therapeutics (NASDAQ:RVNC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.00View SEC Filing  
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.00View SEC Filing  
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.00View SEC Filing  
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.00View SEC Filing  
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.00View SEC Filing  
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.00View SEC Filing  
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.83View SEC Filing  
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.00View SEC Filing  
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
DateHeadline logoREVANCE THERAPEUTICS, INC. Financials (NASDAQ:RVNC) - August 16 at 7:21 PM logoETF’s with exposure to Revance Therapeutics, Inc. : August 15, 2016 (NASDAQ:RVNC) - August 15 at 7:36 PM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : August 12, 2016 (NASDAQ:RVNC) - August 12 at 10:26 AM logoRevance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:RVNC) - August 10 at 7:43 PM logoEdited Transcript of RVNC earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:RVNC) - August 5 at 7:29 PM logoREVANCE THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:RVNC) - August 5 at 7:29 PM
News IconRevance Releases Second Quarter 2016 Results (NASDAQ:RVNC) - August 5 at 10:14 AM logoNew Broker Ratings For Revance Therapeutics Inc (RVNC) - FTSE News (NASDAQ:RVNC) - August 4 at 7:43 PM logoRevance reports 2Q loss (NASDAQ:RVNC) - August 4 at 7:43 PM logoQ2 2016 Revance Therapeutics Inc Earnings Release - After Market Close (NASDAQ:RVNC) - August 4 at 10:26 AM logoRevance Therapeutics Inc (RVNC) Updated Price Targets - FTSE News (NASDAQ:RVNC) - July 25 at 7:22 PM logoShareholder Alert: Sohmer Law Firm Investigating Revance Therapeutics, Inc. (NASDAQ:RVNC) - July 25 at 10:46 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Revance Therapeutics, Inc. (NASDAQ:RVNC) - TGP (NASDAQ:RVNC) - July 21 at 7:35 PM
News IconAre Analysts Bullish Revance Therapeutics Inc (NASDAQ:RVNC) After Last Week? - Consumer Eagle (NASDAQ:RVNC) - July 21 at 7:35 PM logoRevance Therapeutics Inc. (RVNC) Drops 6.81% on July 19 - (NASDAQ:RVNC) - July 21 at 7:35 PM logoRevance Therapeutics Inc (NASDAQ:RVNC) Stock Technicals at Critical Inflection Point - CML News (NASDAQ:RVNC) - July 21 at 7:35 PM logoRevance Therapeutics to Release Second Quarter 2016 Financial Results Thursday, August 4, 2016 (NASDAQ:RVNC) - July 21 at 4:05 PM
News IconIs Selling Revance Therapeutics Inc Here a Winning Strategy? - Consumer Eagle (NASDAQ:RVNC) - July 20 at 10:06 AM
News IconRevance Therapeutics, Inc. (NASDAQ:RVNC): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:RVNC) - July 20 at 10:06 AM
News IconTrading Performance and Target Watch for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph (NASDAQ:RVNC) - July 18 at 12:48 PM logoThese 5 Stocks Are Primed for Breakouts (NASDAQ:RVNC) - July 15 at 2:38 PM logoRevance Therapeutics (RVNC) Completes Pre-Phase 3 Meeting with FDA for RT002 Injectable - (NASDAQ:RVNC) - July 15 at 12:28 PM
News IconCrowd Rating and Earnings Recap for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Telanagana Press (NASDAQ:RVNC) - July 14 at 7:29 PM
News IconEye on Stock Volatility for: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Engelwood Daily (NASDAQ:RVNC) - July 14 at 7:29 PM logo4:03 pm Revance Therapeutics announces it is moving forward with an IND submission for phase 3 clinical program for RT002 & other supportive studies required for the BLA filing after its pre-phase meeting with the FDA (NASDAQ:RVNC) - July 14 at 4:03 PM logoRevance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines (NASDAQ:RVNC) - July 14 at 4:02 PM
News IconHow Analysts Feel About Revance Therapeutics Inc (NASDAQ:RVNC)? - Press Telegraph (NASDAQ:RVNC) - July 13 at 10:06 AM
News IconRevance Therapeutics Incorporated (NASDAQ:RVNC) Sellers Increased By 11.1% Their Shorts - Engelwood Daily (NASDAQ:RVNC) - July 9 at 10:19 AM
News IconNASDAQ:RVNC Stockholder Notice: Investigation of potential Wrongdoing at Revance Therapeutics Inc (NASDAQ:RVNC) - July 7 at 10:00 AM
News IconStock Moving in on a Recent Low: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph (NASDAQ:RVNC) - July 6 at 7:35 PM logoRevance Therapeutics Inc. (RVNC) Drops 5.21% on July 05 - (NASDAQ:RVNC) - July 6 at 7:35 PM
News IconHow Analysts Rated Revance Therapeutics Inc (NASDAQ:RVNC) Last Week? - Press Telegraph (NASDAQ:RVNC) - July 5 at 6:56 PM logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (NASDAQ:RVNC) - July 5 at 4:19 PM logoRevance Appoints Industry Leader Julian S. Gangolli to its Board of Directors (NASDAQ:RVNC) - July 5 at 8:00 AM
News IconShare Performance Recap for: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph (NASDAQ:RVNC) - July 4 at 6:23 PM
News IconRevance Therapeutics Incorporated (NASDAQ:RVNC) Sellers Increased By 11.1% Their Shorts - Press Telegraph (NASDAQ:RVNC) - July 2 at 6:47 PM
News IconEquity Research and Technical Review on Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph (NASDAQ:RVNC) - June 29 at 9:58 AM logoRevance Therapeutics Inc (RVNC) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:RVNC) - June 29 at 9:58 AM logoRevance Therapeutics, Inc. (NasdaqGM:RVNC) Stock Momentum Hits Weakness - CML News (NASDAQ:RVNC) - June 23 at 7:53 PM logoBrokers Issue Average Price Target Of 42.33 On Revance Therapeutics Inc (RVNC) - Fiscal Standard (NASDAQ:RVNC) - June 23 at 7:53 PM
News IconInvestigation for Investors in Shares of Revance Therapeutics Inc (NASDAQ:RVNC) Announced (NASDAQ:RVNC) - June 21 at 11:32 AM logoRevance Therapeutics Inc (RVNC) Analyst Price Targets For The Coming Week - Fiscal Standard (NASDAQ:RVNC) - June 20 at 6:55 PM logoRevance Therapeutics Inc. (RVNC) is Trading Higher on Unusual Volume for June 15 - (NASDAQ:RVNC) - June 17 at 6:58 PM
News IconPerformance report of the company: Revance Therapeutics, Inc. (NASDAQ:RVNC) - News Oracle (NASDAQ:RVNC) - June 15 at 7:08 PM logoRevance Therapeutics Inc. (RVNC) Sank To A New Low On Study Results - RTT News (NASDAQ:RVNC) - June 15 at 7:08 PM logoRevance Therapeutics Inc. (RVNC) Jumps 7.19% on June 15 - (NASDAQ:RVNC) - June 15 at 7:08 PM
News IconTrending Stocks Update: Navistar International Corporation (NYSE:NAV), Revance Therapeutics, Inc. (NASDAQ:RVNC) - Beacon Chronicle (NASDAQ:RVNC) - June 15 at 11:45 AM logoAnalyst Downgrades: Baidu Inc (ADR), Revance Therapeutics Inc, and Chesapeake Energy Corporation - Schaeffers Research (blog) (NASDAQ:RVNC) - June 15 at 11:45 AM logoSummary of Analyst's Study: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Revance Therapeutics, Inc ... - Street Updates (NASDAQ:RVNC) - June 15 at 11:45 AM


Revance Therapeutics (NASDAQ:RVNC) Chart for Tuesday, August, 23, 2016

Last Updated on 8/23/2016 by Staff